George P Giacoia

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Eunice kennedy shriver national institute of child health and human development pediatrics formulation initiative: proceedings from the second workshop on pediatric formulations
    George P Giacoia
    Obstetric and Pediatric Pharmacology Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland Electronic address
    Clin Ther 34:S1-S10. 2012
  2. ncbi Selected Proceedings of the NICHD/FDA newborn drug development initiative: Part II
    George P Giacoia
    Obstetric and Pediatric Pharmacology Branch, Center for Research for Mothers and Children, National Institute of Child Health and Human Development, National Institutes of Health, Rockville, Maryland 20847, USA
    Clin Ther 28:1337-41. 2006
  3. ncbi Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Formulation Initiative: selected reports from working groups
    George P Giacoia
    Obstetric and Pediatric Pharmacology Branch, Center for Research for Mothers and Children, Eunice Kennedy Shriver NICHD, National Institutes of Health, Bethesda, Maryland 20847, USA
    Clin Ther 30:2097-101. 2008
  4. ncbi Drug studies in newborns: a therapeutic imperative
    George P Giacoia
    Obstetric and Pediatric Pharmacology Branch Eunice Kennedy Shriver National Institute of Child Health and Human Development, 6100 Executive Boulevard, Rockville, MD 20852, USA
    Clin Perinatol 39:11-23. 2012
  5. ncbi The newborn drug development initiative
    George P Giacoia
    Obstetric and Pediatric Pharmacology Branch, Center for Research for Mothers and Children, National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland
    Pediatrics 117:S1-8. 2006
  6. ncbi Newborns and drug studies: the NICHD/FDA newborn drug development initiative
    George P Giacoia
    Obstetric and Pediatric Pharmacology Branch, Center for Research for Mothers and Children, National Institute of Child Health and Human Development, National Institutes of Health, Rockville, MD, USA
    Clin Ther 27:796-813. 2005
  7. ncbi Criteria supporting the study of drugs in the newborn
    Robert M Ward
    Department of Pediatrics and the Pediatric Pharmacology Program, University of Utah, Salt Lake City, Utah 84108, USA
    Clin Ther 28:1385-98. 2006
  8. ncbi Antifungals in systemic neonatal candidiasis
    Daniel A C Frattarelli
    Division of Clinical Pharmacology, Children s Hospital of Michigan, Wayne State University School of Medicine, 3901 Beaubien, Detroit, MI 48201, USA
    Drugs 64:949-68. 2004

Collaborators

Detail Information

Publications8

  1. ncbi Eunice kennedy shriver national institute of child health and human development pediatrics formulation initiative: proceedings from the second workshop on pediatric formulations
    George P Giacoia
    Obstetric and Pediatric Pharmacology Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland Electronic address
    Clin Ther 34:S1-S10. 2012
    ....
  2. ncbi Selected Proceedings of the NICHD/FDA newborn drug development initiative: Part II
    George P Giacoia
    Obstetric and Pediatric Pharmacology Branch, Center for Research for Mothers and Children, National Institute of Child Health and Human Development, National Institutes of Health, Rockville, Maryland 20847, USA
    Clin Ther 28:1337-41. 2006
    ..Working groups were established in 3 therapeutic areas: the central nervous, pulmonary, and cardiovascular systems. Three additional groups discussed pain control, drug prioritization, and ethics in neonatal clinical trials...
  3. ncbi Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Formulation Initiative: selected reports from working groups
    George P Giacoia
    Obstetric and Pediatric Pharmacology Branch, Center for Research for Mothers and Children, Eunice Kennedy Shriver NICHD, National Institutes of Health, Bethesda, Maryland 20847, USA
    Clin Ther 30:2097-101. 2008
    ..These groups began the process of identifying issues, gathering needed information, and considering possible ways to overcome barriers to the development of pediatric drug formulations...
  4. ncbi Drug studies in newborns: a therapeutic imperative
    George P Giacoia
    Obstetric and Pediatric Pharmacology Branch Eunice Kennedy Shriver National Institute of Child Health and Human Development, 6100 Executive Boulevard, Rockville, MD 20852, USA
    Clin Perinatol 39:11-23. 2012
    ..The factors that prevent the demonstration of efficacy and safety in the newborn are discussed and a change in the current approach for neonatal drug studies is suggested...
  5. ncbi The newborn drug development initiative
    George P Giacoia
    Obstetric and Pediatric Pharmacology Branch, Center for Research for Mothers and Children, National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland
    Pediatrics 117:S1-8. 2006
    ....
  6. ncbi Newborns and drug studies: the NICHD/FDA newborn drug development initiative
    George P Giacoia
    Obstetric and Pediatric Pharmacology Branch, Center for Research for Mothers and Children, National Institute of Child Health and Human Development, National Institutes of Health, Rockville, MD, USA
    Clin Ther 27:796-813. 2005
    ..Progress has been made in research on the effects of drug therapy on pediatric patients, but neonates are still an understudied population. Those most likely to receive drug therapy (eg, preterm infants) are least likely to be studied...
  7. ncbi Criteria supporting the study of drugs in the newborn
    Robert M Ward
    Department of Pediatrics and the Pediatric Pharmacology Program, University of Utah, Salt Lake City, Utah 84108, USA
    Clin Ther 28:1385-98. 2006
    ..Only one fourth to one third of approved drugs have received adequate pediatric study to permit labeling for treatment of all appropriate pediatric populations...
  8. ncbi Antifungals in systemic neonatal candidiasis
    Daniel A C Frattarelli
    Division of Clinical Pharmacology, Children s Hospital of Michigan, Wayne State University School of Medicine, 3901 Beaubien, Detroit, MI 48201, USA
    Drugs 64:949-68. 2004
    ..Further studies are necessary if the optimisation of antifungal therapy in this population is to continue...